Skip to main content
ToolsForensic AnalysisAUROBINDO PHARMA

AUROBINDO PHARMA

Supplier Forensic Analysis · Scanned: 2026/07/25

Open this supplier in the workbench →

These findings identify statistical unusualness and named data patterns for review. They do not establish wrongdoing and require source verification.

CIPC screening
Clear
Compliance
N/A/100
Awards
3
Total Value
R 2,5B

Recent Awards

3 awards · Total: R 2 522 162 159,15

Showing 5 of 3
HP13-2025ARV/01: Supply and Delivery of Anti-Retroviral Medicines to the Department of Health for the period ending 30 November 2028
Health and Welfare Sector Education and Training Authority
Ref: HP13-2025ARV/01
R 9 821 938,32
19 Jun 2026
HP13-2025ARV: Supply and Delivery of Anti-Retroviral Medicines to the Department of Health for the period 1 July 2025 to 30 June 2028
Health
Ref: HP13-2025ARV
R 1 755 264 015,58
20 Aug 2025
HP13-2022ARV/01: Supply and Delivery of Anti-Retroviral Medicines to the Department of Health for the period ending 30 June 2025.
Health
Ref: HP13-2022ARV/01
R 757 076 205,25
24 Jun 2024

AI Analysis

Powered by Gemini

AI Forensic Analysis

Get AI-generated audit narratives with key findings and recommended actions.
Paid access from R499/mo

or upgrade to Pro Subscription

Procurement context

Competitive concentration, procurement-intelligence context, province health, and restricted-supplier status are available to forensic subscribers.

Unlock forensic context →
CIPC screening signalsClear

No contributing warning signals in the current evidence.

Unlock Full Analysis

Get access to all forensic flags, evidence details, and AI-generated audit narratives.

View Full Intelligence Report

Get complete award history, director network, and compliance analysis.

View Report →